Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Meredith Ann Morgan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7965-6878; OpenAlex author ID A5036484877; NIH RePORTER profile ID 9702151. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 8)
Trials
0
Grants
3
Labs led
1
Collaborators
56
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 1 grant · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 4 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper, 1 grant · 2025: 1 paper · 2026: 1 grant

Papers 20

  1. Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-24-0210↗
  2. Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer. Last author DOI 10.1172/jci.insight.168824↗
  3. DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-21-0725↗
  4. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-20-0365↗
  5. Transgenic expression of Sag/Rbx2 E3 causes early stage tumor promotion, late stage cytogenesis and acinar loss in the Kras-PDAC model. Co-author DOI 10.1016/j.neo.2020.03.002↗
  6. UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2020.100834↗
  7. Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. Co-author DOI 10.1038/s42255-020-0226-5↗
  8. Expansion of Circulating Tumor Cells from Patients with Locally Advanced Pancreatic Cancer Enable Patient Derived Xenografts and Functional Studies for Persona… Co-author DOI 10.3390/cancers12041011↗
  9. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Last author DOI 10.1158/0008-5472.can-19-0761↗
  10. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic C… First author DOI 10.1200/jco.19.00730↗
  11. Prognostic Value of c-MET Expression in Patients With Pancreatic Cancer Receiving Adjuvant and Neoadjuvant Chemoradiation Therapy. First author DOI 10.1016/j.ijrobp.2017.10.030↗
  12. Quantitative Proteomic Analysis of Serum Exosomes from Patients with Locally Advanced Pancreatic Cancer Undergoing Chemoradiotherapy. Co-author DOI 10.1021/acs.jproteome.7b00024↗
  13. Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Co-author DOI 10.1038/srep10867↗
  14. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways. Co-author DOI 10.1080/15384101.2015.1104437↗
  15. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Last author DOI 10.1158/1078-0432.ccr-14-1038↗
  16. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Last author DOI 10.1158/1078-0432.ccr-12-3748↗
  17. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Co-author DOI 10.1158/0008-5472.can-11-2866↗
  18. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Last author DOI 10.1593/neo.12538↗
  19. Role of α(5)β(1) Integrin Up-regulation in Radiation-Induced Invasion by Human Pancreatic Cancer Cells. Co-author DOI 10.1593/tlo.11133↗
  20. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Last author DOI 10.4161/cc.10.24.18661↗

Grants 3

  1. Molecularly Targeted Radiosensitization of Locally Advanced Cancers P50CA269022↗
  2. Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer R01CA240515↗
  3. Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit R01CA163895↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Theodore Steven Lawrence · 16 shared papers, 1 shared grant, 2011–2026 · strength 2.63
  2. Leslie A. Parsels · 10 shared papers, 2011–2025 · strength 0.90
  3. Vaibhav Sahai · 4 shared papers, 2019–2025 · strength 0.52
  4. Qiang Zhang · 3 shared papers, 2022–2025 · strength 0.49
  5. David M. Karnak · 4 shared papers, 2013–2025 · strength 0.39
  6. Victoria M. Valvo · 2 shared papers, 2024–2025 · strength 0.35
  7. Kyle Clifford Cuneo · 4 shared papers, 2017–2020 · strength 0.34
  8. Carl G. Engelke · 4 shared papers, 2013–2021 · strength 0.29
  9. Alnawaz Rehemtulla · 2 shared papers, 2020–2025 · strength 0.28
  10. Dongping Wei · 4 shared papers, 2012–2020 · strength 0.23
  11. Mark M. Zalupski · 3 shared papers, 2015–2019 · strength 0.21
  12. Timothy L. Frankel · 2 shared papers, 2019–2022 · strength 0.21
  13. Jonathan Maybaum · 5 shared papers, 2011–2019 · strength 0.21
  14. Qiang Zhang · 2 shared papers, 2019–2021 · strength 0.21
  15. Sarah Owen · 2 shared papers, 2020 · strength 0.19
  16. Sunitha Nagrath · 2 shared papers, 2020 · strength 0.19
  17. Eileen S. Carpenter · 1 shared paper, 2025 · strength 0.18
  18. Ines Lohse · 2 shared papers, 2017–2020 · strength 0.17
  19. Yi Sun · 2 shared papers, 2012–2020 · strength 0.17
  20. Qiang Zhang · 2 shared papers, 2013–2020 · strength 0.16
  21. Jiaqi Shi · 2 shared papers, 2019–2020 · strength 0.16
  22. Edgar Ben‐Josef · 3 shared papers, 2011–2018 · strength 0.15
  23. Matthew T. McMillan · 1 shared paper, 2022 · strength 0.13
  24. Weiwei Wang · 1 shared paper, 2022 · strength 0.13
  25. Terence Marques Williams · 3 shared papers, 2011–2015 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.